As hypothesized by Carl June, the likelihood of tumor escape through both downregulation of the MHC and loss of the CAR target antigen is expected to be very low, which ultimately means that in dual-specific T cells at least either one, transgenic TCR or CAR, would still work [204]. This evidence concerns the gene HLA-C and neoplasm.